Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refractory Follicular Lymphoma
Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.
Saurabh Dahiya Stanford University School Of Medicine Cell Therapy Division Stanford University School Cancer Cell Therapy Risk Evaluation
Source: onclive.com